Put Options

7 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$33.78 - $63.75 $378,336 - $714,000
11,200 Added 162.32%
18,100 $613,000
Q1 2024

May 15, 2024

SELL
$60.14 - $75.36 $198,462 - $248,688
-3,300 Reduced 32.35%
6,900 $448,000
Q4 2023

Feb 14, 2024

BUY
$42.85 - $69.5 $394,220 - $639,400
9,200 Added 920.0%
10,200 $696,000
Q3 2023

Nov 14, 2023

BUY
$49.5 - $66.6 $49,500 - $66,600
1,000 New
1,000 $51,000
Q1 2023

May 15, 2023

SELL
$46.12 - $65.71 $235,212 - $335,120
-5,100 Reduced 83.61%
1,000 $49,000
Q4 2022

Feb 14, 2023

SELL
$45.51 - $65.08 $423,243 - $605,244
-9,300 Reduced 60.39%
6,100 $348,000
Q3 2022

Nov 14, 2022

BUY
$37.34 - $57.44 $3,734 - $5,744
100 Added 0.65%
15,400 $723,000

Others Institutions Holding IMCR

About Immunocore Holdings plc


  • Ticker IMCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,897,100
  • Market Cap $1.5B
  • Description
  • Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in ...
More about IMCR
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.